Emergent BioSolutions Inc. (EBS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 30.50 |
| Open | 30.36 |
| Bid | 28.85 x 900 |
| Ask | 30.00 x 800 |
| Day's Range | 29.05 - 30.36 |
| 52 Week Range | 26.85 - 65.09 |
| Volume | |
| Avg. Volume | 766,230 |
| Market Cap | 1.465B |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | 17.19 |
| EPS (TTM) | 1.71 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.21 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EBS
Related Research
- Emergent Biosolutions, Inc.Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,400 employees.RatingFair ValueEconomic Moat29 days agoArgus Research
- Benzinga
FDA Issues Warning Letter For Emergent Bio's Manufacturing Facility
The FDA issued a warning letter to Emergent BioSolutions Inc (NYSE: EBS), citing certain deficiencies at the company's troubled manufacturing facility in Baltimore, Maryland. The FDA pointed to equipment cleaning and maintenance deficiencies to prevent drug product contamination. Reuters reported that the agency also recommended that the company review its quality control process. Related: Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract. Emergent had said the FDA had last
- Reuters
Emergent receives FDA warning letter over quality control issues
The FDA pointed to deficiencies in cleaning and maintenance of equipment to prevent contamination of drug product and also recommended the company review its quality control process, Emergent said. Earlier in August, Emergent had said the FDA had last inspected its facility at Camden in February and was waiting for the agency's feedback.
- GlobeNewswire
Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: 12th Annual Midwest IDEAS Investor ConferenceChicago, ILAugust 24, 2022 – presentation scheduled at 5:15 PM central time https://www.wsw.com/webcast/threepa38/ebs/2021448 Wells Fargo 2022 Healthcare ConferenceBoston, MASeptember 8, 2022 – fireside chat scheduled at 9:10 AM easter
